Please login to the form below

Not currently logged in
Email:
Password:

imlygic

This page shows the latest imlygic news and features for those working in and with pharma, biotech and healthcare.

Boehringer bolts on another immuno-oncology company

Boehringer bolts on another immuno-oncology company

Oncolytic virus-based therapies are consistent with and complement that strategy.”. The first oncolytic virus therapy to reach western markets was Amgen’s Imlygic (talimogene laherparepvec or T-Vec) which was

Latest news

More from news
Approximately 5 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Oncolytic viruses. An oncolytic virus is a virus that preferentially infects and kills cancer cells, and to date a handful of therapies – Amgen’s Imlygic (talimogene laherparepvec) in the US and ... While use of Imlygic has been limited, its approval

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics